Ribosomal proteins sustain morphology, function and phenotype in acute myeloid leukemia blasts.
Translation of mRNA is a prerequisite for cell proliferation, differentiation and viability. We have studied the effect of ribosome protein factors (GPRE) on acute myeloid leukemia (AML) blast cells. Ribosomes were isolated from MPC-11 cells using ultra-centrifugation. GPRE were extracted using a high KCl procedure. Blast cells from six AML patients were grown in suspension cultures for 24 and 96 h. GPRE or granulocyte macrophage-colony stimulating factor (GM-CSF) were added at the start of the incubation. GPRE, but not GM-CSF, prevented chromatin condensation and fragmentation of blast cell nuclei in AML-M2, -M4 and -M5 and the loss of nucleoli in AML-M2 and -M5. The fraction of phagocytosing blast cells in AML-M1, -M2, -M4 and -M5 was increased by GPRE. GPRE stimulated opsonin-dependent and -independent attachment and internalisation of N. meningitidis. GPRE increased the fraction of blasts expressing CD11b and CD32 in AML-M2 and -M5. GPRE diminished the fraction of AML-M5 cells bearing CD35 and CD32. GPRE also decreased the fraction of CD11c-bearing AML-M2 and -M5 cells. GM-CSF potentiated effects of GPRE in AML-M1, -M2, -M4 and -M5. GPRE and GM-CSF in combination affected phagocytosis and surface antigen expression in blast cells that were not influenced by either factor alone. Neither GPRE nor GM-CSF induced terminal differentiation or DNA-synthesis. We conclude that GPRE affects AML blast cell morphology, function and surface molecule expression, possibly by inhibiting apoptosis. The effects of GPRE may be mediated by ribosomal proteins that regulate translation and modulate the subcellular distribution of mRNA species.
Bassøe
C F
CF
Medical Department B, Haukeland University Hospital, Bergen, Norway.
Bruserud
O
O
Pryme
I F
IF
Vedeler
A
A
D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002462:Cell Membrane / Q000276:immunology; D002470:Cell Survival; D004247:DNA / Q000096:biosynthesis; D005260:Female; D006651:Histocytochemistry; D006801:Humans; D016167:Integrin alphaXbeta2 / Q000032:analysis; D007951:Leukemia, Myeloid / Q000097:blood / Q000276:immunology / Q000473:pathology*; D007963:Leukocytes, Mononuclear / Q000276:immunology / Q000473:pathology; D008027:Light; D016177:Macrophage-1 Antigen / Q000032:analysis; D008297:Male; D008875:Middle Aged; D010587:Phagocytosis; D010641:Phenotype; D011132:Polyribosomes / Q000737:chemistry; D017463:Receptors, Complement 3b / Q000032:analysis; D017452:Receptors, IgG / Q000032:analysis; D012269:Ribosomal Proteins / Q000032:analysis / Q000235:genetics* / Q000502:physiology*; D012542:Scattering, Radiation; D013997:Time Factors
D016167:Integrin alphaXbeta2; D016177:Macrophage-1 Antigen; D017463:Receptors, Complement 3b; D017452:Receptors, IgG; D012269:Ribosomal Proteins; D004247:DNA